A. D. Beadell Investment Counsel Inc. Has $328,000 Position in Illumina, Inc. (NASDAQ:ILMN)

A. D. Beadell Investment Counsel Inc. lessened its position in Illumina, Inc. (NASDAQ:ILMN) by 7.5% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,457 shares of the life sciences company’s stock after selling 198 shares during the period. A. D. Beadell Investment Counsel Inc.’s holdings in Illumina were worth $328,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the company. Zacks Investment Management acquired a new position in Illumina in the third quarter valued at about $2,924,000. Freemont Management S.A. acquired a new position in shares of Illumina in the 3rd quarter worth approximately $1,565,000. Weybosset Research & Management LLC grew its position in Illumina by 92.0% during the 3rd quarter. Weybosset Research & Management LLC now owns 18,052 shares of the life sciences company’s stock worth $2,354,000 after acquiring an additional 8,650 shares during the last quarter. B. Riley Wealth Advisors Inc. increased its holdings in Illumina by 176.3% during the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 7,176 shares of the life sciences company’s stock valued at $749,000 after purchasing an additional 4,579 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its position in Illumina by 65.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 32,806 shares of the life sciences company’s stock valued at $4,278,000 after purchasing an additional 12,986 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on ILMN shares. Robert W. Baird raised their target price on Illumina from $124.00 to $139.00 and gave the company a “neutral” rating in a research note on Wednesday, November 6th. Hsbc Global Res raised shares of Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 target price for the company in a research note on Thursday, October 17th. Canaccord Genuity Group increased their price target on shares of Illumina from $130.00 to $145.00 and gave the company a “hold” rating in a research note on Tuesday, November 5th. TD Cowen boosted their price objective on shares of Illumina from $166.00 to $177.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $156.00 target price on shares of Illumina in a research note on Tuesday, November 12th. Eight equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $165.95.

Illumina Trading Down 3.6 %

ILMN stock traded down $5.02 during midday trading on Friday, hitting $134.66. 470,069 shares of the company’s stock were exchanged, compared to its average volume of 1,245,201. Illumina, Inc. has a one year low of $100.08 and a one year high of $156.66. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. The company has a market cap of $21.36 billion, a PE ratio of -13.52 and a beta of 1.11. The stock’s fifty day moving average price is $141.37 and its 200-day moving average price is $132.08.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The business had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.08 billion. During the same quarter in the previous year, the business posted $0.33 EPS. Illumina’s revenue for the quarter was down 3.5% on a year-over-year basis. Research analysts predict that Illumina, Inc. will post 4.11 earnings per share for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.